Maxim Group Initiates a Buy Rating on Synthetic Biologics (SYN)

In a report released yesterday, Jason McCarthy from Maxim Group initiated coverage with a Buy rating on Synthetic Biologics (SYN) and a price target of $2.50. The company’s shares closed last Friday at $0.47, close to its 52-week low of $0.25.

According to, McCarthy is a 5-star analyst with an average return of 33.1% and a 42.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Lineage Cell Therapeutics, and Monopar Therapeutics Inc.

Currently, the analyst consensus on Synthetic Biologics is a Moderate Buy with an average price target of $2.50.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.70 and a one-year low of $0.25. Currently, Synthetic Biologics has an average volume of 12.23M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts